Jiaxue Wu

Dr. Jiaxue Wu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2021 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
WGWenqing Gao
Wenqing Gao
YLYuanyuan Li
Yuanyuan Li
XLXuehe Liu
Xuehe Liu
SWSen Wang
Sen Wang
PMPucheng Mei
Pucheng Mei
JLJixi Li
Jixi Li

5 May 2021 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
PMPucheng Mei
Pucheng Mei
FXFeiyan Xie
Feiyan Xie
JPJiasong Pan
Jiasong Pan
SWSen Wang
Sen Wang
WGWenqing Gao
Wenqing Gao
JLJixi Li
Jixi Li
Receptor interacting protein kinase 3 (RIP3 or RIPK3), the critical executor of cell programmed necrosis, plays essential roles in maintaining immune responses and appropriate tissue homeostasis. Although the E3 ligases CHIP and PELI1 are reported to promote RIP3 degradation, however, how post-translational modification regulates RIP3 activity and stability is poorly understood. Here, we identify the tripartite motif protein TRIM25 as a negative regulator of RIP3-dependent necrosis. TRIM25 directly interacts with RIP3 through its SPRY domain and mediates the K48-linked polyubiquitination of RIP3 on residue K501. The RING domain of TRIM25 facilitates the polyubiquitination chain on RIP3, thereby promoting proteasomal degradation of RIP3. Also, TRIM25 deficiency inhibited the ubiquitination of RIP3, thus promoting TNF-induced cell necrosis. Our current finding reveals the regulating mechanism of polyubiquitination on RIP3, which might be a potential therapeutic target for the intervention of RIP3-dependent necrosis-related diseases.

8 March 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
YZYahui Zhao
Yahui Zhao
XHXiaoding Hu
Xiaoding Hu
LWLi Wei
Li Wei
DSDan Song
Dan Song
JWJuanjuan Wang
Juanjuan Wang
JWJiaxue Wu
Jiaxue Wu

10 July 2017 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
JWJuanjuan Wang
Juanjuan Wang
CZChenggang Zhu
Chenggang Zhu
DSDan Song
Dan Song
RXRuiqi Xia
Ruiqi Xia
WYWenbo Yu
Wenbo Yu
JWJiaxue Wu
Jiaxue Wu
Poly(ADP-ribose) polymerases (PARPs) are ADP-ribosylating enzymes and play important roles in a variety of cellular processes. Most small-molecule PARP inhibitors developed to date have been against PARP1, a poly-ADP-ribose transferase, and suffer from poor selectivity. PARP16, a mono-ADP-ribose transferase, has recently emerged as a potential therapeutic target, but its inhibitor development has trailed behind. Here we newly characterized epigallocatechin-3-gallate (EGCG) as a potential inhibitor of PARP16. We found that EGCG was associated with PARP16 and dramatically inhibited its activity in vitro. Moreover, EGCG suppressed the ER stress-induced phosphorylation of PERK and the transcription of unfolded protein response-related genes, leading to dramatically increase of cancer cells apoptosis under ER stress conditions, which was dependent on PARP16. These findings newly characterized EGCG as a potential inhibitor of PARP16, which can enhance the ER stress-induced cancer cell apoptosis, suggesting that a combination of EGCG and ER stress-induced agents might represent a novel approach for cancer therapy or chemoprevention.

28 August 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CSChangjuan Shao
Changjuan Shao
YQYangyang Qiu
Yangyang Qiu
JLJuan Liu
Juan Liu
HFHuan Feng
Huan Feng
SSSuqin Shen
Suqin Shen
JWJiaxue Wu
Jiaxue Wu
PARP12 is a mono-ADP-ribosyltransferase, but its function remains largely unknown. Here, we identified four-and-a-half LIM-only protein 2 (FHL2) as a functional partner of PARP12 through protein affinity purification. Although PARP12 did not mono-ADP-ribosylate FHL2 in vitro and in vivo, PARP12 deficiency decreased the protein level of FHL2 by promoting its ubiquitination and increased the expression level of transforming growth factor beta1 (TGF-β1), which is independent of PARP12 enzymatic activity. We also provided evidence that PARP12 deficiency increased the migration and invasion of hepatocellular carcinoma (HCC) cells and promoted HCC metastasis in vivo by regulating the epithelial–mesenchymal transition process. These results indicated that PARP12 is a tumor suppressor that plays an important role in HCC metastasis through the regulation of FHL2 stability and TGF-β1 expression.

11 October 2017 in Tumor Biology
Verified
Journal Article
Open access
TCTianran Chen
Tianran Chen
CLChuan Liu
Chuan Liu
HLHeng Lu
Heng Lu
MYMingzhen Yin
Mingzhen Yin
CSChangjuan Shao
Changjuan Shao
YWYajie Wang
Yajie Wang
Triple-negative breast cancer is a kind of breast cancer with poor prognosis and special biological behavior, which lacked endocrine therapy and targeted therapy. We investigate the effect of human APE1 (apurinic/apyrimidyl endonuclease 1), a rate-limiting enzyme of base excision repair, on the prognosis in triple-negative breast cancer and drug sensitivity of olaparib. The expression of APE1 was detected by immunohistochemistry in the triple-negative breast cancer tissues and its effect on survival of triple-negative breast cancer patients was followed. To find whether APE1 effect the drug sensitivity in triple-negative breast cancer cells, the APE1-knockout HCC1937 cell line (triple-negative breast cancer cell line) was established by CRISPR/Cas9 system. Then, we use the wild-type and knockout one to test the drug sensitivity of olaparib. The expression of APE1 in triple-negative breast cancer tissues was significantly higher than that in the adjacent tissues (85.6% vs 14.4%) and its expression was related to tumor size (p < 0.05). We also found that it is an independent prognostic factor in patients with triple-negative breast cancer (overall survival, p = 0.01). In vitro assay, the half maximal inhibitory concentration of olaparib in HCC1937-APE1-KO was significantly increased (17.22 vs 91.85 μM) compared to the wild type. The growth curve showed that olaparib had a stronger lethality on HCC1937 compared to HCC1937- APE1-KO (p < 0.05 on day 3). HCC1937 resulted in more mitotic G2/M arrest and increased apoptosis rate after treatment with 40 μM of olaparib, while HCC1937-APE1-KO did not change significantly. When HCC1937 was treated with different concentrations of olaparib, it was found that APE1 expression decreased more significantly at 15 μM of olaparib was. In HCC1937-APE1-KO, the expression of endogenous poly (ADP-ribose) polymerase 1 was also less than that of HCC1937. These results suggested that the expression of APE1 was an important basis for the maintenance of poly (ADP-ribose) polymerase 1, and the deletion of APE1 may be related to the resistance of olaparib.